Request an Appointment



Contact us with Questions

Expand Content

Ramon Tiu, MD


Ramon Tiu, MD
Department: Translational Hematology and Oncology Research
Associate Staff
Location: Cleveland Clinic Main Campus
Mail Code R40
9500 Euclid Avenue
Cleveland, OH 44195
Ramon Tiu, MD
Department: Hematology and Oncology
Associate Staff
Location: Cleveland Clinic Main Campus
Mail Code R40
9500 Euclid Avenue
Cleveland, OH 44195
Ramon Tiu, MD
Department: Genomic Medicine Institute
Associate Staff
Location: Cleveland Clinic Main Campus
Mail Code R40
9500 Euclid Avenue
Cleveland, OH 44195
Adults Only

Biographical Sketch

Ramon Tiu is an Assistant Professor of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and is associate staff in the Department of Translational Hematology and Oncology Research and Department of Hematologic Oncology and Blood Disorders at Cleveland Clinic. He completed his medical school training at the University of Santo Tomas Faculty of Medicine and Surgery in the Philippines and subsequently pursued internal medicine training at Cleveland Clinic from 2003-2006. He pursued further research training in experimental hematology as a bone marrow failure research fellow at Cleveland Clinic under the tutelage of Dr. Jaroslaw P. Maciejewski, which he continued throughout his fellowship training in hematology and oncology at the same institution. He is well published in the area of single nucleotide polymorphism arrays, especially in their clinical application in myeloid malignancies like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). He is a young investigator awardee from the MDS Foundation and the Aplastic Anemia and MDS International Foundation and a prior recipient of a T32 research award from Case Western Reserve University. He is involved in both clinical and translational research, focusing mainly on the field of myeloproliferative neoplasms and bone marrow failure syndromes. His laboratory research team recently identified a gene called SF3B1 to be frequently mutated in cases of MDS with ring sideroblasts, specifically refractory anemia with ring sideroblasts (RARS) and RARS associated with marked thrombocytosis (RARS-T). SF3B1 is a gene involved in an important physiologic post-transcriptional process called splicing. This is an unprecedented finding, as this is the first time that the spliceosome machinery has been implicated as a possible cause in blood cancers, particularly in MDS. Recently, his research team showed the first experimental evidence linking SF3B1 dysfunction and the formation of ring sideroblast in MDS. He is also very active in conducting clinical trials in bone marrow failure syndromes and myeloproliferative neoplasms (MPNs) and an active clinician seeing patients with MDS, MDS/MPN overlap syndromes, MPNs and rare bone marrow failure conditions like Aplastic Anemia, PNH and LGL leukemia. He is board certified in Internal Medicine, Hematology and Oncology.

Education & Fellowships

Fellowship - Cleveland Clinic
Hematology & Oncology
Cleveland, OH USA
Research Fellowship - Cleveland Clinic
Experimental Hematology
Cleveland, OH USA
Residency - Cleveland Clinic
Internal Medicine
Cleveland, OH USA
Internship - Cleveland Clinic
Internal Medicine
Cleveland, OH USA
Medical School - University of Santo Tomas Faculty of Medicine & Surgery
Manila Philippines
Undergraduate - De La Salle University
Manila Philippines


  • Internal Medicine
  • Internal Medicine- Medical Oncology
  • Internal Medicine- Hematology

Specialty Interests

Myeloproliferative disorders/neoplasms myelodysplastic syndromes, large granular lymphocyte leukemia, aplastic anemia, paroxysmal nocturnal hemoglobinuria, pure red cell aplasia, cancer, pancytopenia, leukemia, cytopenia, chronic myelomonocytic leukemia (CMML)

Awards & Honors

  • Scott Hamilton CARES Grant Awardee, 2012
  • American Cancer Society Pilot Grant, 2012
  • 1st American Society of Hematology Advocacy Leadership Institute, 2011
  • Clinical and Translational Science Collaborative Annual Pilot Award, 2010
  • Aplastic Anemia & MDS International Foundation Research Grant Awardee (Torry Yahn Research Fund), 2010
  • European Hematology Association/ American Society of Hematology 1st Translational Research Training in Hematology, 2009
  • Celgene Future Leaders in Hematology Award for Clinical Research, 2009
  • MDS Foundation 5th Annual Young Investigators Grant, 2009
  • American Association for Cancer Research Methods of Clinical Cancer Research Workshop Participant, 2009
  • Cancer Education Consortium Molecular and Translational Oncology Workshop Travel Grant, 2009
  • Mayo Clinic Hematology/Oncology Fellows' Research Awards recipient, 2008
  • American Society of Hematology Travel Award, Atlanta, GA, 2007
  • "Tito Bastianello" Young Investigator Award 9th International Symposium on Myelodysplastic Syndromes. Florence, Italy, 2007
  • Honorable Mention 10th annual CCF Internal Medicine Resident Research Scholar Competition, 2005


  • American Society of Hematology
  • American Association for Cancer Research
  • American Society of Clinical Oncology

Treatment & Services

  • Chemotherapy
  • Clinical Trials
  • Experimental Therapeutics
  • Hematology & Oncology Screenings and Disorders

Specialty in Diseases and Conditions

  • Aplastic Anemia
  • Blood Disorders
  • Cancer
  • Chronic Myelomonocytic Leukemia (CMML)
  • Cytopenia
  • Large Granular Lymphocytic Leukemia
  • Myelodysplastic Syndrome (MDS)
  • Myeloproliferative Disorders
  • Myeloproliferative Neoplasms
  • Pancytopenia
  • Paroxysmal Nocturnal Hemoglobinuria

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 2/5/2014, Dr. Tiu has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Tiu receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Bristol-Myers Squibb
  • Incyte Corporation
  • Novartis Pharmaceuticals Corporation
  • Teva Pharmaceutical Industries, Ltd.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English
  • Filipino